Boehringer Ingelheim

RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, CA, dedicated to advancing treatments for patients suffering from inflammatory and immunologic diseases. The company's innovative approach focuses on developing therapeutics that intelligently target key drivers of the immune system to transform treatment outcomes and enhance the quality of life for countless individuals. With a commitment to addressing conditions such as food allergies and other allergic diseases, RAPT Therapeutics is at the forefront of scientific research and development. The company aims to empower patients through cutting-edge therapies, exemplified by their long-acting anti-IgE antibody, RPT904, which is designed to make a significant difference in the lives of those affected. Generated from the website

Principia Biopharma Inc, located in South San Francisco, CA, is a biopharmaceutical company dedicated to advancing innovative treatments in immunology, neurology, oncology, rare blood disorders, rare diseases, and vaccines. With a focus on social impact and responsible business values, the company is committed to improving access to healthcare and driving environmental sustainability. Through their cutting-edge science and diverse pipeline of medicines, Principia Biopharma Inc aims to make a positive impact on global health. Their dedication to scientific collaboration, clinical trial results, and partnerships demonstrates a commitment to advancing healthcare solutions for patients worldwide.Generated from the website

Napo Pharmaceuticals, Inc. is a San Francisco-based company dedicated to developing and commercializing prescription medicines that provide essential supportive care for individuals undergoing treatment for diseases like cancer. Their mission is to improve the comfort, quality of life, and dignity of patients experiencing treatment-related gastrointestinal distress, particularly overactive bowel symptoms such as chronic diarrhea, urgency, and incontinence. Napo Pharmaceuticals is currently focused on their Phase 3 pivotal OnTarget trial of Mytesi crofelemer, a preventative treatment for chemotherapy-induced overactive bowel, with comprehensive results expected in Q1 2024. They also support investigator-initiated studies exploring the potential of crofelemer for rare disease indications like short bowel syndrome and microvillus inclusion disease. Napo Pharmaceuticals takes pride in their responsible harvesting practices, sourcing their medicines from plants in rainforest regions. Their prescription medicines work through a novel mechanism of action, inhibitory modulation of two secretory chloride ion channels in the gastrointestinal tract. The company is committed to uncovering medical solutions to serve those in need, advancing their understanding through high-quality research conducted by external investigators. Environmental sustainability and social responsibility are paramount to Napo Pharmaceuticals, as they prioritize the responsible harvesting of their products and share benefits with the local communities that contribute to their mission.Generated from the website